BioNTech's long-term outlook helped it shrug off a first-quarter loss and sinking revenue as demand for COVID-19 vaccines ...
Germany's BioNTech , whose COVID-19 vaccine in partnership with Pfizer was widely used during the pandemic, said on Monday ...
Advancing toward goal of ten or more potentially registrational trials running by the end of 2024: first patient dosed in Phase 3 clinical trial ...
Vaccine availability is on a first-come, first-served basis and while supplies last. Updated bivalent Pfizer-BioNTech and Moderna COVID-19 vaccines and boosters will be available at the clinics. The ...
People who got the COVID-19 booster had stronger protection against the virus that causes the disease compared to people who ...
Pfizer-BioNTech, Moderna, Sanofi/GSK and Novavax. Those getting the spring booster will be given an mRNA vaccine made by either Pfizer or Moderna. Both have been updated to help protect against ...
A new study shows that immunity after a COVID-19 booster lasts much longer than the primary series alone. These findings are among other, sometimes 'unintuitive,' revelations of how factors like age, ...
GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents ...
COVID vaccine booster shots were rolled out, and about 40 percent of US adults said they did not plan on getting a booster.
April 25 (Reuters) - GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the ...
Advancing toward goal of ten or more potentially registrational trials running by the end of 2024: first patient dosed in Phase 3 clinical trial evaluating BNT323/DB-1303 in HR+ HER2-low chemotherapy- ...
The lawsuit adds to a web of high-stakes U.S. court cases involving Pfizer, BioNTech and Moderna over patent royalties for technology used in their vaccines, including a case brought by Moderna ...